IOVANCE BIOTHERAPEUTICS, INC. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Iovance reported Q3 2026 product revenue of $122M (vs. $67.5M in Q3 2025, +80% YoY), with U.S. Amtagvi revenue at $102M (+77% YoY). Gross margin expanded to ~60% from 56% in Q2 2026. The company reaffirmed full-year 2026 guidance of $410–420M total revenue. Cash position stands at ~$382M as of September 30, 2026, expected to fund operations into 2029. Key pipeline milestones include 24.6% ORR in 69 mNSCLC patients (IOV-LUN-202), 59.1% ORR in biomarker-selected mNSCLC (POSITILITY trial initiated), and 55.6% ORR in UPS/DDLPS (SARATOGA registrational trial ongoing).
Why this rating
Revenue +80% YoY to $122M and margin expansion are substantial for a $534.8M market-cap company; represents meaningful commercial traction. Pipeline data and regulatory progress (Fast Track designations, sBLA planning) support medium-term growth. Not transformational alone but significant commercial and clinical validation.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-7.7% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $9.31 ▲ 10.65% | at our read · unknown $8.41 | +10 min · unknown $8.42 ▲ 0.05% | +30 min · unknown $8.19 ▼ 2.67% | +1 hr · unknown $8.56 ▲ 1.72% | +4 hrs · unknown $7.75 ▼ 7.96% |
The stock had already moved -9.62% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.